Principles of using tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD). Recommendations of the Working Group of the Polish Society of Nephrology

Abstract

Tolvaptan, a vasopressin type 2 receptor antagonist, is currently the only disease-modifying drug available for autosomal dominant polycystic kidney disease (ADPKD). The following recommendations discuss patients’ eligibility for tolvaptan treatment and its monitoring while providing a practical supplement to the Summary of Product Characteristics of the medicinal product Jinarc (Otsuka).